Moderna (MRNA) Stock
Fundamentals
Recent news

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
MRNA

Moderna to replace Warner Bros Discovery on Nasdaq 100
Moderna to replace Warner Bros Discovery on Nasdaq 100
MRNA

Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
MRNA

Moderna, Merck Rally On Cancer Vaccine Promise. But Is The Multi-Billion-Dollar Hype Real?
Moderna, Merck Rally On Cancer Vaccine Promise. But Is The Multi-Billion-Dollar Hype Real?
MRNA
Technical indicators
- RSI 14
- 66.22
- MACD 12/26/9
- 19.90
- EMA 9 of MACD
- 20.02
- MACD histogram
- -0.12
- SMA 50
- $123.63
- Price above SMA 50
- EMA 50
- $136.97
- Price above EMA 50
- SMA 200
- $68.39
- Price above SMA 200
- EMA 200
- $78.03
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 2, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 13 analysts
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$2.09 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
SLS, IBRX Stocks Climb Overnight: Retail Eyes Moderna’s Rally As MRNA Lands A Nasdaq-100 Spot
MRNA

Moderna to replace Warner Bros Discovery on Nasdaq 100
Moderna to replace Warner Bros Discovery on Nasdaq 100
MRNA

Moderna (MRNA) Stock Dips While Market Gains: Key Facts
Moderna (MRNA) Stock Dips While Market Gains: Key Facts
MRNA

Moderna, Merck Rally On Cancer Vaccine Promise. But Is The Multi-Billion-Dollar Hype Real?
Moderna, Merck Rally On Cancer Vaccine Promise. But Is The Multi-Billion-Dollar Hype Real?
MRNA

Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
MRNA

Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz
MRNA

Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
Moderna Stock Slumps as Citi Says It's Time to Sell After 500% Rally This Year
MRNA

Prediction: Moderna Stock Will Soar 100% by 2030
Prediction: Moderna Stock Will Soar 100% by 2030
MRNA

Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
MRNA

Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings
MRNA
About Moderna
Since our founding in 2010, we have worked to build the industry's leading messenger RNA (mRNA) technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Stéphane Bancel M.B.A. | CEO & Director | 1973 |
| Dr. Stephen Hoge M.D. | President | 1976 |
| Mr. James M. Mock | Chief Financial Officer | 1977 |
| Ms. Shannon Thyme Klinger J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Technical indicators
- RSI 14
- 66.22
- MACD 12/26/9
- 19.90
- EMA 9 of MACD
- 20.02
- MACD histogram
- -0.12
- SMA 50
- $123.63
- Price above SMA 50
- EMA 50
- $136.97
- Price above EMA 50
- SMA 200
- $68.39
- Price above SMA 200
- EMA 200
- $78.03
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 2, 2026. Technical data, not a recommendation.
Analyst views
13 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $38.00
- Average
- $93.09
- High
- $180.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +14.1 | +4.5 | -18.2 | |||||||||
| 2022 | -28.0 | -11.1 | +15.2 | -23.9 | +2.3 | -0.4 | +9.4 | -18.1 | -14.9 | +24.2 | +13.8 | -1.0 |
| 2023 | -1.6 | -20.4 | +13.2 | -16.7 | -4.3 | -5.5 | -3.3 | -0.8 | -8.2 | -26.5 | +2.0 | +24.6 |
| 2024 | -10.2 | -6.8 | +12.1 | +4.5 | +27.9 | -19.7 | +2.8 | -17.8 | -8.4 | -15.0 | -21.2 | -6.1 |
| 2025 | -6.1 | -15.3 | -6.3 | +5.1 | -1.7 | +2.0 | +3.0 | -12.7 | +6.8 | -1.6 | +4.3 | +22.1 |
| 2026 | +42.8 | +25.9 | -3.9 | -8.2 | +4.0 | +52.0 | -24.4 | +154.5 | +24.8 | +0.6 |



